MYOM2 and plasma cell myeloma: To further demonstrate the utility of the proposed methods, we applied it to the M-protein data from the Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone (VISTA) trial [41].